Advanced Search

Oncology & Hematology Coding Alert

HCPCS 2011:

J9302, J9307, and J9315 Offer New Options for Lymph Cancer Drugs

Published on Tue Nov 09, 2010

Watch for these drugs when other treatments have failed.You'll have a trio of new J codes for leukemia and lymphoma treatments available for use in January.J9302 Answers Call for Arzerra CodeIf you provide Arzerra injections, take heed of new code J9302 (Injection, ofatumumab, 10 mg). Oncologists typically use the medication to treat chronic lymphocytic leukemia in adults who have not responded satisfactorily to fludarabine or alemtuzumab.As the suffix -mab in ofatumumab indicates, this medication is a monoclonal antibody.Note: Hospitals previously had a C code available for this agent, C9260 (Injection, ofatumumab, 10 mg). HCPCS 2011 deletes this code. (Remember that C codes are appropriate only for Hospital Outpatient Prospective Payment System claims.)Focus on J9307 for FolotynAnother new J code for 2011 is J9307 (Injection, pralatrexate, 1 mg), which is appropriate for Folotyn.Oncologists typically use this folate analogue metabolic inhibitor to kill cancer cells in patients with peripheral T-cell lymphoma that [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All